Form 4: Teva Pharmaceutical Director Gerald Lieberman Reports Share Transactions
SEC Form 4 Filing
Director Gerald Lieberman reports the vesting and conversion of restricted share units into ordinary shares of Teva Pharmaceutical Industries.
Summary
- On June 15, 2024, Gerald M. Lieberman, a director of Teva Pharmaceutical Industries, reported transactions involving restricted share units.
- 21,108 restricted share units vested and were converted into 21,108 ordinary shares.
- Following the transaction, Lieberman directly owns 106,025 ordinary shares.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing insider transactions, which carries a neutral sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors.
Key Dates
| Date | Description |
|---|---|
| 06/15/2023 | Restricted Share Units were granted |
| 06/15/2024 | Restricted Share Units vested and converted into ordinary shares |
| 06/17/2024 | Date of report filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.